View Future GrowthSilva Pharmaceuticals 과거 순이익 실적과거 기준 점검 0/6Silva Pharmaceuticals 의 수입은 연평균 -70.8%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 5.8%의 비율로 증가했습니다. 매출은 연평균 16.6%의 비율로 감소해 왔습니다.핵심 정보-70.82%순이익 성장률-70.81%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률11.00%매출 성장률-16.56%자기자본이익률-7.66%순이익률-46.78%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트공고 • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2026 Results on Apr 28, 2026Silva Pharmaceuticals Limited announced that they will report Q3, 2026 results on Apr 28, 2026공고 • Jan 25Silva Pharmaceuticals Limited to Report Q2, 2026 Results on Jan 29, 2026Silva Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jan 29, 2026공고 • Nov 10Silva Pharmaceuticals Limited to Report Q1, 2026 Results on Nov 13, 2025Silva Pharmaceuticals Limited announced that they will report Q1, 2026 results on Nov 13, 2025공고 • Oct 21Silva Pharmaceuticals Limited to Report Fiscal Year 2025 Results on Oct 28, 2025Silva Pharmaceuticals Limited announced that they will report fiscal year 2025 results on Oct 28, 2025공고 • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2025 Results on Apr 28, 2025Silva Pharmaceuticals Limited announced that they will report Q3, 2025 results on Apr 28, 2025공고 • Jan 23Silva Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 30, 2025Silva Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 30, 2025모든 업데이트 보기Recent updatesNew Risk • Jun 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Bangladeshi stocks, typically moving 7.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.6% average weekly change). Earnings have declined by 71% per year over the past 5 years. Minor Risks Revenue is less than US$5m (৳330m revenue, or US$2.7m). Market cap is less than US$100m (৳1.94b market cap, or US$15.8m).Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director A. T. M. Sarrowar Chowdhury was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2026 Results on Apr 28, 2026Silva Pharmaceuticals Limited announced that they will report Q3, 2026 results on Apr 28, 2026공고 • Jan 25Silva Pharmaceuticals Limited to Report Q2, 2026 Results on Jan 29, 2026Silva Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jan 29, 2026공고 • Nov 10Silva Pharmaceuticals Limited to Report Q1, 2026 Results on Nov 13, 2025Silva Pharmaceuticals Limited announced that they will report Q1, 2026 results on Nov 13, 2025공고 • Oct 29Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2025Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2025, at 11:30 Central Asia Standard Time. Location: hybrid system, Bangladesh공고 • Oct 21Silva Pharmaceuticals Limited to Report Fiscal Year 2025 Results on Oct 28, 2025Silva Pharmaceuticals Limited announced that they will report fiscal year 2025 results on Oct 28, 2025공고 • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2025 Results on Apr 28, 2025Silva Pharmaceuticals Limited announced that they will report Q3, 2025 results on Apr 28, 2025공고 • Jan 23Silva Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 30, 2025Silva Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 30, 2025New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (৳1.42b market cap, or US$11.8m).공고 • Nov 09Silva Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 13, 2024Silva Pharmaceuticals Limited announced that they will report Q1, 2025 results on Nov 13, 2024New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (৳1.52b market cap, or US$12.6m).Declared Dividend • Oct 31Dividend of ৳0.10 announcedDividend of ৳0.10 is the same as last year. Ex-date: 2nd December 2024 Payment date: 29th January 2025 Dividend yield will be 1.0%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (117% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments.공고 • Oct 29Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2024Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2024, at 10:30 Central Asia Standard Time. Location: hybrid system, BangladeshNew Risk • Oct 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ৳1.19b (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 31% per year over the past 5 years. Market cap is less than US$10m (৳1.19b market cap, or US$9.94m).공고 • Oct 21Silva Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 28, 2024Silva Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Oct 28, 2024Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳0.041 (vs ৳0.061 in 3Q 2023)Third quarter 2024 results: EPS: ৳0.041 (down from ৳0.061 in 3Q 2023). Revenue: ৳174.3m (down 13% from 3Q 2023). Net income: ৳5.62m (down 33% from 3Q 2023). Profit margin: 3.2% (down from 4.2% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.공고 • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 28, 2024Silva Pharmaceuticals Limited announced that they will report Q3, 2024 results on Apr 28, 2024Reported Earnings • Feb 03Second quarter 2024 earnings released: ৳0.063 loss per share (vs ৳0.14 profit in 2Q 2023)Second quarter 2024 results: ৳0.063 loss per share (down from ৳0.14 profit in 2Q 2023). Revenue: ৳151.3m (down 18% from 2Q 2023). Net loss: ৳8.56m (down 145% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has remained flat, which means it is well ahead of earnings.공고 • Jan 24Silva Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024Silva Pharmaceuticals Limited announced that they will report Q2, 2024 results on Jan 29, 2024Upcoming Dividend • Nov 27Upcoming dividend of ৳0.10 per share at 0.5% yieldEligible shareholders must have bought the stock before 04 December 2023. Payment date: 28 January 2024. Payout ratio is a comfortable 72% but the company is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%).공고 • Nov 07Silva Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 13, 2023Silva Pharmaceuticals Limited announced that they will report Q1, 2024 results on Nov 13, 2023공고 • Oct 31Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2023The Board of Directors of Silva Pharmaceuticals Limited has recommended 1% Cash Dividend for all shareholders for the year ended June 30, 2023.공고 • Oct 30Silva Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023Silva Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023, at 11:30 Bangladesh Standard Time.공고 • Oct 20Silva Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Oct 29, 2023Silva Pharmaceuticals Limited announced that they will report fiscal year 2023 results on Oct 29, 2023Reported Earnings • May 17Third quarter 2023 earnings released: EPS: ৳0.061 (vs ৳0.22 in 3Q 2022)Third quarter 2023 results: EPS: ৳0.061 (down from ৳0.22 in 3Q 2022). Revenue: ৳200.2m (down 1.9% from 3Q 2022). Net income: ৳8.38m (down 72% from 3Q 2022). Profit margin: 4.2% (down from 15% in 3Q 2022). The decrease in margin was primarily driven by higher expenses.Upcoming Dividend • Nov 27Upcoming dividend of ৳0.30 per shareEligible shareholders must have bought the stock before 04 December 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 57% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Muhammad Moniruzzaman was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Nov 01Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022The Board of Directors of Silva Pharmaceuticals Limited has recommended 3% cash dividend for shareholders excluding the Sponsors/Directors (except 1.5% for ICB) for the year ended June 30, 2022. The total amount of cash dividend payable to the general shareholders including ICB is BDT 24,189,812.00 only for 94,983,000 shares.Reported Earnings • May 28Third quarter 2022 earnings released: EPS: ৳0.22 (vs ৳0.19 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.22 (up from ৳0.19 in 3Q 2021). Revenue: ৳204.0m (up 6.6% from 3Q 2021). Net income: ৳30.1m (up 18% from 3Q 2021). Profit margin: 15% (up from 13% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • May 24Investor sentiment improved over the past weekAfter last week's 16% share price gain to ৳24.90, the stock trades at a trailing P/E ratio of 29.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 20% over the past three years.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Muhammad Moniruzzaman was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 18% share price gain to ৳21.90, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 3.6% over the past three years.Reported Earnings • Feb 09Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: ৳0.22 (up from ৳0.20 in 2Q 2021). Revenue: ৳196.0m (up 2.6% from 2Q 2021). Net income: ৳29.8m (up 11% from 2Q 2021). Profit margin: 15% (up from 14% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year.Upcoming Dividend • Nov 25Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 02 December 2021. Payment date: 30 January 2022. Trailing yield: 2.7%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.8%).Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳24.80, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 23% over the past year.Reported Earnings • Feb 03Second quarter 2021 earnings released: EPS ৳0.20 (vs ৳0.27 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ৳190.9m (down 5.6% from 2Q 2020). Net income: ৳26.9m (down 24% from 2Q 2020). Profit margin: 14% (down from 17% in 2Q 2020). The decrease in margin was driven by lower revenue.공고 • Jul 17Silva Pharmaceuticals Limited to Report Q3, 2020 Results on Jul 02, 2020Silva Pharmaceuticals Limited announced that they will report Q3, 2020 results on Jul 02, 2020매출 및 비용 세부 내역Silva Pharmaceuticals가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DSE:SILVAPHL 매출, 비용 및 순이익 (BDT Millions)날짜매출순이익일반관리비연구개발비31 Mar 26330-154227031 Dec 25357-145225030 Sep 25371-136219030 Jun 25384-133222031 Mar 25432-132229031 Dec 24498-107225030 Sep 24547-90218030 Jun 24600-64210031 Mar 24612-31200031 Dec 23638-28197030 Sep 236710192030 Jun 2371733186031 Mar 2374557177031 Dec 2274978176030 Sep 2276089174030 Jun 22779102175031 Mar 22805119181031 Dec 21793115179030 Sep 21788112177030 Jun 21799120172031 Mar 21780116153031 Dec 20776118153030 Sep 20788126150030 Jun 20763119158031 Mar 20769126164031 Dec 19767133153030 Sep 19756131150030 Jun 19732143144031 Mar 19725136136031 Dec 18707125132030 Sep 18695123129030 Jun 1868593128031 Mar 18687100126030 Jun 1760280114030 Jun 1658670880양질의 수익: SILVAPHL 은(는) 현재 수익성이 없습니다.이익 마진 증가: SILVAPHL는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: SILVAPHL은 수익성이 없으며 지난 5년 동안 손실이 연평균 70.8% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 SILVAPHL의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: SILVAPHL은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(10.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: SILVAPHL는 현재 수익성이 없으므로 자본 수익률이 음수(-7.66%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/13 20:52종가2026/07/13 00:00수익2026/03/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Silva Pharmaceuticals Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2026 Results on Apr 28, 2026Silva Pharmaceuticals Limited announced that they will report Q3, 2026 results on Apr 28, 2026
공고 • Jan 25Silva Pharmaceuticals Limited to Report Q2, 2026 Results on Jan 29, 2026Silva Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jan 29, 2026
공고 • Nov 10Silva Pharmaceuticals Limited to Report Q1, 2026 Results on Nov 13, 2025Silva Pharmaceuticals Limited announced that they will report Q1, 2026 results on Nov 13, 2025
공고 • Oct 21Silva Pharmaceuticals Limited to Report Fiscal Year 2025 Results on Oct 28, 2025Silva Pharmaceuticals Limited announced that they will report fiscal year 2025 results on Oct 28, 2025
공고 • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2025 Results on Apr 28, 2025Silva Pharmaceuticals Limited announced that they will report Q3, 2025 results on Apr 28, 2025
공고 • Jan 23Silva Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 30, 2025Silva Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 30, 2025
New Risk • Jun 30New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Bangladeshi stocks, typically moving 7.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.6% average weekly change). Earnings have declined by 71% per year over the past 5 years. Minor Risks Revenue is less than US$5m (৳330m revenue, or US$2.7m). Market cap is less than US$100m (৳1.94b market cap, or US$15.8m).
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director A. T. M. Sarrowar Chowdhury was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2026 Results on Apr 28, 2026Silva Pharmaceuticals Limited announced that they will report Q3, 2026 results on Apr 28, 2026
공고 • Jan 25Silva Pharmaceuticals Limited to Report Q2, 2026 Results on Jan 29, 2026Silva Pharmaceuticals Limited announced that they will report Q2, 2026 results on Jan 29, 2026
공고 • Nov 10Silva Pharmaceuticals Limited to Report Q1, 2026 Results on Nov 13, 2025Silva Pharmaceuticals Limited announced that they will report Q1, 2026 results on Nov 13, 2025
공고 • Oct 29Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2025Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2025, at 11:30 Central Asia Standard Time. Location: hybrid system, Bangladesh
공고 • Oct 21Silva Pharmaceuticals Limited to Report Fiscal Year 2025 Results on Oct 28, 2025Silva Pharmaceuticals Limited announced that they will report fiscal year 2025 results on Oct 28, 2025
공고 • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2025 Results on Apr 28, 2025Silva Pharmaceuticals Limited announced that they will report Q3, 2025 results on Apr 28, 2025
공고 • Jan 23Silva Pharmaceuticals Limited to Report Q2, 2025 Results on Jan 30, 2025Silva Pharmaceuticals Limited announced that they will report Q2, 2025 results on Jan 30, 2025
New Risk • Nov 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (৳1.42b market cap, or US$11.8m).
공고 • Nov 09Silva Pharmaceuticals Limited to Report Q1, 2025 Results on Nov 13, 2024Silva Pharmaceuticals Limited announced that they will report Q1, 2025 results on Nov 13, 2024
New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Bangladeshi stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 31% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (৳1.52b market cap, or US$12.6m).
Declared Dividend • Oct 31Dividend of ৳0.10 announcedDividend of ৳0.10 is the same as last year. Ex-date: 2nd December 2024 Payment date: 29th January 2025 Dividend yield will be 1.0%, which is lower than the industry average of 2.5%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. The dividend is also not covered by cash flows (117% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments.
공고 • Oct 29Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2024Silva Pharmaceuticals Limited, Annual General Meeting, Dec 30, 2024, at 10:30 Central Asia Standard Time. Location: hybrid system, Bangladesh
New Risk • Oct 29New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ৳1.19b (US$9.94m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 31% per year over the past 5 years. Market cap is less than US$10m (৳1.19b market cap, or US$9.94m).
공고 • Oct 21Silva Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Oct 28, 2024Silva Pharmaceuticals Limited announced that they will report fiscal year 2024 results on Oct 28, 2024
Reported Earnings • May 02Third quarter 2024 earnings released: EPS: ৳0.041 (vs ৳0.061 in 3Q 2023)Third quarter 2024 results: EPS: ৳0.041 (down from ৳0.061 in 3Q 2023). Revenue: ৳174.3m (down 13% from 3Q 2023). Net income: ৳5.62m (down 33% from 3Q 2023). Profit margin: 3.2% (down from 4.2% in 3Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 64 percentage points per year, which is a significant difference in performance.
공고 • Apr 24Silva Pharmaceuticals Limited to Report Q3, 2024 Results on Apr 28, 2024Silva Pharmaceuticals Limited announced that they will report Q3, 2024 results on Apr 28, 2024
Reported Earnings • Feb 03Second quarter 2024 earnings released: ৳0.063 loss per share (vs ৳0.14 profit in 2Q 2023)Second quarter 2024 results: ৳0.063 loss per share (down from ৳0.14 profit in 2Q 2023). Revenue: ৳151.3m (down 18% from 2Q 2023). Net loss: ৳8.56m (down 145% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
공고 • Jan 24Silva Pharmaceuticals Limited to Report Q2, 2024 Results on Jan 29, 2024Silva Pharmaceuticals Limited announced that they will report Q2, 2024 results on Jan 29, 2024
Upcoming Dividend • Nov 27Upcoming dividend of ৳0.10 per share at 0.5% yieldEligible shareholders must have bought the stock before 04 December 2023. Payment date: 28 January 2024. Payout ratio is a comfortable 72% but the company is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of Bangladeshi dividend payers (3.4%). Lower than average of industry peers (2.5%).
공고 • Nov 07Silva Pharmaceuticals Limited to Report Q1, 2024 Results on Nov 13, 2023Silva Pharmaceuticals Limited announced that they will report Q1, 2024 results on Nov 13, 2023
공고 • Oct 31Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2023The Board of Directors of Silva Pharmaceuticals Limited has recommended 1% Cash Dividend for all shareholders for the year ended June 30, 2023.
공고 • Oct 30Silva Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023Silva Pharmaceuticals Limited, Annual General Meeting, Dec 28, 2023, at 11:30 Bangladesh Standard Time.
공고 • Oct 20Silva Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Oct 29, 2023Silva Pharmaceuticals Limited announced that they will report fiscal year 2023 results on Oct 29, 2023
Reported Earnings • May 17Third quarter 2023 earnings released: EPS: ৳0.061 (vs ৳0.22 in 3Q 2022)Third quarter 2023 results: EPS: ৳0.061 (down from ৳0.22 in 3Q 2022). Revenue: ৳200.2m (down 1.9% from 3Q 2022). Net income: ৳8.38m (down 72% from 3Q 2022). Profit margin: 4.2% (down from 15% in 3Q 2022). The decrease in margin was primarily driven by higher expenses.
Upcoming Dividend • Nov 27Upcoming dividend of ৳0.30 per shareEligible shareholders must have bought the stock before 04 December 2022. Payment date: 29 January 2023. Payout ratio is a comfortable 57% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (2.5%).
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Muhammad Moniruzzaman was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Nov 01Silva Pharmaceuticals Limited Recommends Cash Dividend for the Year Ended June 30, 2022The Board of Directors of Silva Pharmaceuticals Limited has recommended 3% cash dividend for shareholders excluding the Sponsors/Directors (except 1.5% for ICB) for the year ended June 30, 2022. The total amount of cash dividend payable to the general shareholders including ICB is BDT 24,189,812.00 only for 94,983,000 shares.
Reported Earnings • May 28Third quarter 2022 earnings released: EPS: ৳0.22 (vs ৳0.19 in 3Q 2021)Third quarter 2022 results: EPS: ৳0.22 (up from ৳0.19 in 3Q 2021). Revenue: ৳204.0m (up 6.6% from 3Q 2021). Net income: ৳30.1m (up 18% from 3Q 2021). Profit margin: 15% (up from 13% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • May 24Investor sentiment improved over the past weekAfter last week's 16% share price gain to ৳24.90, the stock trades at a trailing P/E ratio of 29.7x. Average trailing P/E is 23x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 20% over the past three years.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 6 non-independent directors. Independent Director Muhammad Moniruzzaman was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 18% share price gain to ৳21.90, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total loss to shareholders of 3.6% over the past three years.
Reported Earnings • Feb 09Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: ৳0.22 (up from ৳0.20 in 2Q 2021). Revenue: ৳196.0m (up 2.6% from 2Q 2021). Net income: ৳29.8m (up 11% from 2Q 2021). Profit margin: 15% (up from 14% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 12% per year.
Upcoming Dividend • Nov 25Upcoming dividend of ৳0.50 per shareEligible shareholders must have bought the stock before 02 December 2021. Payment date: 30 January 2022. Trailing yield: 2.7%. Lower than top quartile of Bangladeshi dividend payers (3.0%). Higher than average of industry peers (1.8%).
Valuation Update With 7 Day Price Move • Sep 26Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳24.80, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 25x in the Pharmaceuticals industry in Bangladesh. Total returns to shareholders of 23% over the past year.
Reported Earnings • Feb 03Second quarter 2021 earnings released: EPS ৳0.20 (vs ৳0.27 in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ৳190.9m (down 5.6% from 2Q 2020). Net income: ৳26.9m (down 24% from 2Q 2020). Profit margin: 14% (down from 17% in 2Q 2020). The decrease in margin was driven by lower revenue.
공고 • Jul 17Silva Pharmaceuticals Limited to Report Q3, 2020 Results on Jul 02, 2020Silva Pharmaceuticals Limited announced that they will report Q3, 2020 results on Jul 02, 2020